Skip to Main Content

Paper Details

The Role of Chemotherapy Plus Immune Checkpoint Inhibitors in Oncogenic-Driven NSCLC: A University of California Lung Cancer Consortium Retrospective Study.
JTO Clin Res Rep
6
2022
Cancer, Lung Cancer, Oncogenic-Driven NSCLC, V600, advanced lung cancer, patient, patients, tyrosine, tyrosine kinase
Author NameAffiliation
Jason W ChanUniversity of California san francisco
Amy L CummingsDavid Geffen School of Medicine, University of California Los Angeles
Amy L CummingsDavid Geffen School of Medicine, University of California Los Angeles
Jonathan W GoldmanDavid Geffen School of Medicine, University of California Los Angeles
Jonathan W GoldmanDavid Geffen School of Medicine, University of California Los Angeles
Matthew A GubensUniversity of California San Francisco
  • 1 - 6

Datasets

Release 1.2